Open AccessFDA Acknowledges Activity in Romiplostim for ITP, but Asks ODAC to Evaluate Safety
Author(s) -
Margot J. Fromer
Publication year - 2008
Publication title -
oncology times
Language(s) - English
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000317228.01702.66
Subject(s) - medicine , romiplostim , rituximab , incidence (geometry) , etiology , cancer , pediatrics , antibody , immunology , thrombopoietin , genetics , stem cell , haematopoiesis , biology , physics , optics